De Sire R, La Mantia A, Bonacci L, Testa A, Guarino A, Rispo A
Life (Basel). 2025; 14(12.
PMID: 39768250
PMC: 11678131.
DOI: 10.3390/life14121541.
Mukherjee S, Batagello C, Adler A, Agudelo J, Zampini A, Suryavanshi M
bioRxiv. 2024; .
PMID: 39553961
PMC: 11565779.
DOI: 10.1101/2024.10.28.620613.
Cellini B, Baum M, Frishberg Y, Groothoff J, Harris P, Hulton S
Kidney Int Rep. 2024; 9(11):3083-3096.
PMID: 39534212
PMC: 11551133.
DOI: 10.1016/j.ekir.2024.08.031.
Singh A, Khanna T, Mahendru D, Kahlon J, Kumar V, Sohal A
World J Nephrol. 2024; 13(3):96574.
PMID: 39351187
PMC: 11439091.
DOI: 10.5527/wjn.v13.i3.96574.
Samra M, Gupta I
Cureus. 2024; 16(8):e67409.
PMID: 39310402
PMC: 11414766.
DOI: 10.7759/cureus.67409.
Metabolic Profile of Calcium Oxalate Stone Patients with Enteric Hyperoxaluria and Impact of Dietary Intervention.
Siener R, Ernsten C, Welchowski T, Hesse A
Nutrients. 2024; 16(16).
PMID: 39203825
PMC: 11357492.
DOI: 10.3390/nu16162688.
Revisional one-anastomosis gastric bypass for failed laparoscopic sleeve gastrectomy.
Binda A, Zurkowska J, Gonciarska A, Kudlicka E, Barski K, Jaworski P
Updates Surg. 2024; 76(6):2267-2275.
PMID: 38594580
DOI: 10.1007/s13304-024-01820-8.
Engineered microorganisms: A new direction in kidney stone prevention and treatment.
Wan W, Wu W, Amier Y, Li X, Yang J, Huang Y
Synth Syst Biotechnol. 2024; 9(2):294-303.
PMID: 38510204
PMC: 10950756.
DOI: 10.1016/j.synbio.2024.02.005.
Intestinal Oxalate Absorption, Enteric Hyperoxaluria, and Risk of Urinary Stone Formation in Patients with Crohn's Disease.
Siener R, Ernsten C, Speller J, Scheurlen C, Sauerbruch T, Hesse A
Nutrients. 2024; 16(2).
PMID: 38257157
PMC: 10821467.
DOI: 10.3390/nu16020264.
Hydration for Adult Patients with Nephrolithiasis: Specificities and Current Recommendations.
Courbebaisse M, Travers S, Bouderlique E, Michon-Colin A, Daudon M, De Mul A
Nutrients. 2023; 15(23).
PMID: 38068743
PMC: 10708476.
DOI: 10.3390/nu15234885.
Frequency and impact of enteric hyperoxaluria in pediatric short bowel syndrome: a retrospective single centre study.
Schaefer J, Schulz-Heise S, Rueckel A, Rauh M, Juengert J, Galiano M
Front Pediatr. 2023; 11:1157696.
PMID: 37502194
PMC: 10369460.
DOI: 10.3389/fped.2023.1157696.
A Case of Oxalate Nephropathy Associated With Prolonged Cholecystostomy Tube Placement.
Hale A, Anderson D, Eineichner T, De Souza C, Smirlis E, Adio B
Cureus. 2023; 15(6):e40797.
PMID: 37485127
PMC: 10362807.
DOI: 10.7759/cureus.40797.
Oxalate Homeostasis in Non-Stone-Forming Chronic Kidney Disease: A Review of Key Findings and Perspectives.
Stepanova N
Biomedicines. 2023; 11(6).
PMID: 37371749
PMC: 10296321.
DOI: 10.3390/biomedicines11061654.
Oxalate nephropathy in an elderly patient with newly diagnosed celiac disease - a case report.
Zijlstra H, Stegeman C
BMC Nephrol. 2023; 24(1):189.
PMID: 37370009
PMC: 10294398.
DOI: 10.1186/s12882-023-03241-y.
Acetate attenuates hyperoxaluria-induced kidney injury by inhibiting macrophage infiltration via the miR-493-3p/MIF axis.
Zhu W, Wu C, Zhou Z, Zhang G, Luo L, Liu Y
Commun Biol. 2023; 6(1):270.
PMID: 36922584
PMC: 10017675.
DOI: 10.1038/s42003-023-04649-w.
Oxalate homeostasis.
Ermer T, Nazzal L, Tio M, Waikar S, Aronson P, Knauf F
Nat Rev Nephrol. 2022; 19(2):123-138.
PMID: 36329260
PMC: 10278040.
DOI: 10.1038/s41581-022-00643-3.
Increased Rates of Supplement-Associated Oxalate Nephropathy During COVID-19 Pandemic.
Fong P, Wusirika R, Rueda J, Raphael K, Rehman S, Stack M
Kidney Int Rep. 2022; 7(12):2608-2616.
PMID: 36120391
PMC: 9464307.
DOI: 10.1016/j.ekir.2022.09.002.
Renal and Urological Disorders Associated With Inflammatory Bowel Disease.
Kumar S, Pollok R, Goldsmith D
Inflamm Bowel Dis. 2022; 29(8):1306-1316.
PMID: 35942657
PMC: 10393213.
DOI: 10.1093/ibd/izac140.
Oxalate crystal-related acute renal injury caused by orlistat: A case report.
Cui X, Chen X, Li Y, Fu X, Song P, Xiao L
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022; 47(5):583-587.
PMID: 35753728
PMC: 10929923.
DOI: 10.11817/j.issn.1672-7347.2022.210393.
Small-molecule inhibitor of intestinal anion exchanger SLC26A3 for treatment of hyperoxaluria and nephrolithiasis.
Cil O, Chu T, Lee S, Haggie P, Verkman A
JCI Insight. 2022; 7(13).
PMID: 35608921
PMC: 9310519.
DOI: 10.1172/jci.insight.153359.